In neuroblastoma, patients with high levels of GRHL1 expression show favorable prognosis, consistent with the suppressed tumor growth phenotype seen in the xenografts carrying forced GRHL1 expression in MYCN-amplified neuroblastoma cells (Fabian et al., 2014). This evidence concerns the gene MYCN and neuroblastoma.